| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/28/2001 | EP1077995A1 Antiangiogenic drug to treat cancer, arthritis and retinopathy |
| 02/28/2001 | EP1077994A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same |
| 02/28/2001 | EP1077989A1 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene |
| 02/28/2001 | EP1077980A2 Epothilone derivatives, a method for the production thereof, and their use |
| 02/28/2001 | EP1077978A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 02/28/2001 | EP1077974A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 02/28/2001 | EP1077971A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| 02/28/2001 | EP1077964A1 Fumagillol derivatives and processes for preparing the same |
| 02/28/2001 | EP1077949A2 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
| 02/28/2001 | EP1077946A1 Fused tricyclic compounds which inhibit parp activity |
| 02/28/2001 | EP1077945A1 Isoquinolines as urokinase inhibitors |
| 02/28/2001 | EP1077944A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| 02/28/2001 | EP1077943A1 Heterocyclic inhibitors of p38 |
| 02/28/2001 | EP1077937A1 METHOD OF LOCKING 1$g(a)-OH OF VITAMIN D COMPOUNDS IN AXIAL ORIENTATION |
| 02/28/2001 | EP1077928A1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 02/28/2001 | EP1077927A1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 02/28/2001 | EP1077729A2 Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| 02/28/2001 | EP1077728A1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy |
| 02/28/2001 | EP1077724A2 Methods and products related to metabolic interactions in disease |
| 02/28/2001 | EP1077722A2 Methods and products for inducing mucosal immunity |
| 02/28/2001 | EP1077720A2 Composition for inducing a tumor-specific immune response, method for the production and utilization of said composition in the treatment of neoplasia |
| 02/28/2001 | EP1077715A1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
| 02/28/2001 | EP1077712A1 Adenovirus-chemotherapeutic combination for treating cancer |
| 02/28/2001 | EP1077709A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| 02/28/2001 | EP1077698A1 Metabolites of ecteinascidin 743 |
| 02/28/2001 | CN1285874A Desaturase genes and their use |
| 02/28/2001 | CN1285845A VEGI, an inhibitor of angiogenesis and tumor growth |
| 02/28/2001 | CN1285751A Antimutagenic compositions for treatment and prevention of photodamage to skin |
| 02/28/2001 | CN1285744A Use of histamine for elevating blood histamine levels |
| 02/28/2001 | CN1285743A Process for production of arsenic trioxide formulations and methods for treating cancer using arsenic troxide or melarsoprol |
| 02/28/2001 | CN1285351A Taxane with alkyl subtituted lateral chain and medicinal composition containing said compound |
| 02/28/2001 | CN1062561C 7-halo-and 7beta, 8 beta-methano-taxols, antineoplastic use and pharmaceutical compositions containing them |
| 02/28/2001 | CN1062555C Substituted benzyloxy carbonyl guanidine, its prepn. method, and application of the same as medicament and medicament containing the same |
| 02/28/2001 | CN1062554C Substituted guanidine cinnamate, its prepn., its application as medicine or diagnosing agent and medicine containing the compound |
| 02/28/2001 | CN1062451C Formulation of asparagus syrup and prepn thereof |
| 02/27/2001 | US6194601 5,6-dihydronaphthalenyl derivatives having retinoid-like activity |
| 02/27/2001 | US6194579 Providing quantity of 7-keto camptothecin; selectively substituting leaving group at c7 carbon of 7-keto camptothecin; selectively derivatizing c7 carbon |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194451 Prevent release tumor necrosis factor; antiinflammatory agents |
| 02/27/2001 | US6194448 N, N-disubstituted amides that inhibit the binding of integrins to their receptors |
| 02/27/2001 | US6194439 Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| 02/27/2001 | US6194438 Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives |
| 02/27/2001 | US6194437 Non-peptide bombesin receptor antagonists |
| 02/27/2001 | US6194425 Viricides, antitumor agents |
| 02/27/2001 | US6194401 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid |
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194386 Labelled peptide compounds |
| 02/27/2001 | US6194207 Methods for the selective expansion of lymphocytes by in vitro cultivation |
| 02/27/2001 | US6194206 Use of oligonucleotide telomerase inhibitors to reduce telomere length |
| 02/27/2001 | US6194205 Multistep process using conditionally immortalized antigen-presenting cells which are engineered to express antigen of interest, adding leukocytic cells, and culturing mixture to activate the t cells |
| 02/27/2001 | US6194187 Apoptosis-inducing protein and gene encoding the same |
| 02/27/2001 | US6194186 Human protein kinase and kinase inhibitors |
| 02/27/2001 | US6194181 Producing epothiolones in a culture medium by providing microorganisms such as myxobacteria which produce epothiolones, and adding a complex-forming agent soluble in the culture medium, such as cyclodextrins; antitumor agents |
| 02/27/2001 | US6194171 Also vectors, transformed cells; useful for expression in cells for the purposes of identifying agonists or antagonists of ataxin-2-binding protein function |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6193970 Potentiating local inflammatory or immune response to administration of tumor antigen in mammalian subject by administering tumor antigen in form of tumor cells, or subcellular antigenic material and cytokine or cytokines |
| 02/27/2001 | US6193966 Administering bispecific protein or peptide molecule, comprising a first binding determinate which binds to fc.alpha.receptor without being blocked by immunoglobulin a and second binding determinant which binds to target antigen |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6193963 Method of treating tumor-bearing patients with human plasma hyaluronidase |
| 02/27/2001 | CA2107485C Ellipticin derivatives, their preparation process and pharmaceutical compositions containing them |
| 02/27/2001 | CA2066031C Methods for reducing non-target retention of immunoconjugates and metabolites thereof |
| 02/27/2001 | CA2022177C Arginine deiminase, its manufacturing method, and an anti-cancer agent containing this enzyme as an effective ingredient |
| 02/27/2001 | CA1341191C Detection of neu gene expression and products |
| 02/22/2001 | WO2001013117A2 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012818A1 Neutral cerebral-sphingomyelinase |
| 02/22/2001 | WO2001012811A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/22/2001 | WO2001012809A2 Heterodimeric vegf variants used for inhibiting angiogenesis |
| 02/22/2001 | WO2001012806A2 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012786A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012781A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012674A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012665A2 Helical cytokine zalpha48 |
| 02/22/2001 | WO2001012664A2 Notch receptor ligands and uses thereof |
| 02/22/2001 | WO2001012663A2 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | WO2001012662A2 Membrane associated proteins |
| 02/22/2001 | WO2001012655A1 Peptides consisting of fragments of gli-1 and sufuh and their use |
| 02/22/2001 | WO2001012648A1 Novel transcription factor, bp1 |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012632A2 Phenanthroline-7-one derivatives and their therapeutic uses |
| 02/22/2001 | WO2001012631A2 Ascididemin derivatives and their therapeutic applications |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012579A2 New stilbenes with vascular damaging activity |
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012227A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/22/2001 | WO2001012218A1 Methods and materials for the treatment of prostatic carcinoma |